Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda, a specialty pharmaceutical company, has gained a registration approval for Astepro, a new nasal spray for the treatment of allergic rhinitis, in Europe.
Subscribe to our email newsletter
The company expects to launch the nasal spray product in 2013.
National registration processes, including price and reimbursement, will now follow in each country, the company said.
Meda CEO Anders Lonner said the product has been launched in the US with good success.
"With the addition of Dymista (currently in registration phase) Meda will have an extraordinary strong position in the allergy rhinitis area, both in the US and Europe", Lonner added.